Clinical Trial Update: Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 pilot study evaluating neoadjuvant chemoradiation combined with an EGFR tyrosine kinase inhibitor for potentially resectable pancreatic cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• EGFR Tyrosine Kinase Inhibitor (EGFR tyrosine kinase inhibitor)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED